Skip to content
RDL Network logo
Figure S3 from Phase I First-in-Human Study of TRK-950, an IgG1 Antibody Specific to CAPRIN-1, in Patients with Advanced Solid Tumors — Philippe A. Cassier (2025) | RDL Network